• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Lymphoblastic Lymphoma - Pipeline Review, H2 2012 Product Image

Lymphoblastic Lymphoma - Pipeline Review, H2 2012

  • Published: December 2012
  • 73 pages
  • Global Markets Direct

Lymphoblastic Lymphoma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Lymphoblastic Lymphoma - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lymphoblastic Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lymphoblastic Lymphoma. Lymphoblastic Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lymphoblastic Lymphoma.
- A review of the Lymphoblastic Lymphoma products under development by companies READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Lymphoblastic Lymphoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Lymphoblastic Lymphoma 8
Lymphoblastic Lymphoma Therapeutics under Development by Companies 10
Lymphoblastic Lymphoma Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Lymphoblastic Lymphoma Therapeutics – Products under Development by Companies 15
Lymphoblastic Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Lymphoblastic Lymphoma Therapeutics Development 17
Bristol-Myers Squibb Company 17
Sanofi-Aventis 18
Novartis AG 19
Pfizer Inc. 20
Lymphoblastic Lymphoma – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
SAR-245409 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Therapeutic allogeneic lymphocytes program - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cytarabine + Dacogen + Doxorubicin + Pegaspargase + Prednisone + Vincristine + Vorinostat - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
PF-03084014 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Hyper-CVAD + Filgrastim + Nelarabine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 38
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
rituximab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Fludarabine + Thiotepa + Allogeneic Stem Cell Transplantation - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
Cytarabine + Dacogen + Doxorubicin + Imatinib + Methotrexate + Pegaspargase + Prednisone + Vincristine + SAHA - Drug Profile 46
Product Description 46
Mechanism of Action 47
R&D Progress 48
Rituximab + Fludarabine + Etoposide + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone + Filgrastim + Cytarabine + Cyclosporine + Allogeneic Stem Cell Transplantation + Donor Lymphocyte Infusion - Drug Profile 49
Product Description 49
Mechanism of Action 50
R&D Progress 51
Nelarabine + Etoposide + Cyclophosphamide + Methotrexate + Filgrastim - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
nelarabine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Clofarabine + Etoposide + Asparaginase + Mitoxantrone + Dexamethasone - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 57
BMS-906024 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Rituximab + Cyclophosphamide + Prednisone + Dexamethasone + Vincristine + Methotrexate + Ifosphamide + Teniposide + Etoposide + Cytarabine + Adriamycin + Vindesine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 61
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
HSC-835 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Lymphoblastic Lymphoma Therapeutics – Drug Profile Updates 65
Lymphoblastic Lymphoma Therapeutics – Discontinued Products 66
Lymphoblastic Lymphoma Therapeutics - Dormant Products 67
Lymphoblastic Lymphoma – Product Development Milestones 68
Featured News & Press Releases 68
Dec 13, 2011: Immunomedics Announces Results From Phase II Trial Of Epratuzumab At Hematology Conference 68
Dec 11, 2011: Micromet's Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma 68
Dec 05, 2010: Pharmacyclics Reports Positive Results From Phase I Study Of PCI-32765 At ASH Annual Meeting 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Lymphoblastic Lymphoma, H2 2012 8
Products under Development for Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Bristol-Myers Squibb Company, H2 2012 17
Sanofi-Aventis, H2 2012 18
Novartis AG, H2 2012 19
Pfizer Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Lymphoblastic Lymphoma Therapeutics – Drug Profile Updates 65
Lymphoblastic Lymphoma Therapeutics – Discontinued Products 66
Lymphoblastic Lymphoma Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Lymphoblastic Lymphoma, H2 2012 8
Products under Development for Lymphoblastic Lymphoma – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos